TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05643950

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foley catheter
Description: Silicone Foley catheters are transurethral balloon catheters used for the treatment of bladder emptying disorders, as well as for drainage of urine from the urinary tract, continuous fluid irrigation, and/or medication administration. Its use is suitable for a prolonged period of no more than 29 days and is used in Urology, Internal Medicine, Surgery, Obstetrics and Gynaecology Services.~For this study, conventional Foley-type catheters whose use is approved in Spain for routine use will be used. Silicone Foley catheters, usually available in 2- and 3-way, are made of silicone and consist of a body, drainage funnel, inflation funnel, irrigation funnel (if present, only on 3-way catheters) and balloon valve. The product is sterile and single use.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: T-Control catheter
Description: The T-control® catheter is a flexible, sterile silicone tube with an inflatable balloon at the distal tip, a polytetrafluroethylene membrane integrated into its body, and a sliding fluid control valve. The valve, built into the catheter, provides additional functions to the catheter, such as turning urine flow on and off after insertion (functions currently provided by accessories such as caps or valves) and controlling urination during the insertion process (function that is not provided by any other device). In this way, accidental loss of urine can be avoided from the first moment of use until its withdrawal. Additionally, it has a safety cap that reduces the possibility of accidental movements of the valve before use or during transport and fixing. The design has been developed in such a way that, once inserted, it facilitates autonomous use even for the elderly or patients with limited manual dexterity. The device is sterile and single use, like any conventional Foley catheter.
Study: NCT05287893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyronaridine
Description: Single dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: P. falciparum IBSM infection
Description: Induced Blood Stage Malaria
Study: NCT06705153

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laughter yoga
Description: Patients who come to the outpatient clinic will be met, informed about the study and written informed consent will be obtained from patients who agree to participate in the study. Patient information form will be applied, baseline measurements will be made (IBS-SSS, DAS-42, PSQI and IBS-QOL) and IBS type will be determined according to Bristol stool scale. Type 1-2 constipation, Type 6-7 diarrhea, Type 1 or Type 2 at the same time with Type 6 or Type 7 will be considered as mixed type IBS and those who do not fit any of the scales will be considered as unclassifiable IBS. A total of 8 sessions will be held with the patients in the intervention group in the form of meetings via zoom with the help of a smart cell phone/computer (2 weekly sessions). The meetings will be in 3 groups.
Study: NCT06707623

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory Physiotherapy
Description: Physiotherapy will include: Progressive breathing retraining, neurosensory training, nose breathing training, activity modification, inhalation-exhalation ratio training, dynamic respiratory control training and instructions for continuing all of the above training at home. Total 5 sessions in 9 weeks time.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation
Description: Pulmonary Rehabilitation will be completed in 16 sessions (2 times a week for 8 weeks). It will combine exercise with breathing retraining guided by CPET findings regarding erratic breathing pattern and/or hyperventilation.
Study: NCT06715891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raphamin
Description: Tablet for oral use.
Study: NCT06583616

Intervention type: DIAGNOSTIC_TEST
Intervention: Anion Gap
Description: Patient with acute pulmonary embolism who not survive after hospitalization
Study: NCT06715891

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet for oral use.
Study: NCT06723561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4.5mg daily dose of naltrexone
Description: Study subjects will take a daily 4.5mg dose of naltrexone.
Study: NCT06724367

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transspinal direct current stimulation
Description: Direct current electrical stimulation applied non-invasively to the spinal cord.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator
Description: transspinal direct current stimulation simulated
Study: NCT06530966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICP-332 Tablets
Description: Eligible patients will receive ICP-332 tablets orally as per the protocol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ICP-332 Placebo Tablets
Description: Eligible patients will receive ICP-332 placebo tablets orally as per the protocol
Study: NCT06732713

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Swiss Ball
Description: Swiss ball exercises will be performed in supine, sitting and standing position for about 25 to 30 minutes , 3 to 4 sessions per week for 8 weeks
Study: NCT05214248

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: a multimedia admission orientation
Description: A short video based on self-drawing characters and figures with Chinese dubbing and background light music, explaining the NICU environment, health care workers, and tests and examination that are essential for an infant admitted to this NICU of Cathay Hospital in Taipei, R.O.C.
Study: NCT06732713

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Frenkel exercise
Description: Frenkel exercises will be performed in supine, sitting and standing position for about 25 to 30 minutes, 3 to 4 sessions per week for 8 weeks
Study: NCT06722742

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine only
Description: Inj: Ketamine given to group K following spinal anesthesia
Study: NCT06309745

Intervention type: PROCEDURE
Intervention: retroperitoneal lymph node dissection
Description: retroperitoneal lymph node dissection

Intervention type: DRUG
Intervention: Carboplatin AUC10
Description: Carboplatin AUC10
Study: NCT06722742

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: Inj Tramadol given to group T following spinal anesthesia
Study: NCT06737705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baritinib
Description: Participants will receive additional baritinib administration with 4-mg dosage once daily (QD) for consecutive 14 days after randomization (adjusted dosage of 2-mg QD for participants with eGFR between 30-60 mL/min/1.73m\^2).
Study: NCT06754605

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCTV02
Description: Participants will receive a singe dose of SCTV02 on Day 0.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCTV02
Description: Participants will receive a singe dose of SCTV02 on Day 0.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCTV02
Description: Participants will receive a singe dose of SCTV02 on Day 0.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCTV02
Description: Participants will receive a singe dose of SCTV02 on Day 0.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCTV02
Description: Participants will receive a singe dose of SCTV02 on Day 0.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCTV02
Description: Participants will receive a singe dose of SCTV02 on Day 0.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a singe dose of Placebo on Day 0.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a singe dose of Placebo on Day 0.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a singe dose of Placebo on Day 0.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a singe dose of Placebo on Day 0.
Study: NCT06757322

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Singel Needle Double Cannula TMJ Arthrocentesis
Description: Artocentesis describes the lavage of the TMJ by introducing a saline/ringer lactate solution through a needle inserted into the upper joint cavity. TMJ arthrocentesis was first introduced as a double needle entry method by Nitzan et al in 1991. The single needle technique was developed by Singh and Varghese and introduced in 2013. The single needle method is a more simplified modification of the first method.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Double Needle TMJ Arthrocentesis
Description: Artocentesis describes the lavage of the TMJ by introducing a saline/ringer lactate solution through a needle inserted into the upper joint cavity. TMJ arthrocentesis was first introduced as a double needle entry method by Nitzan et al in 1991.
Study: NCT06756425

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: aerobic exercise program
Description: aerobic exercise program for 3 months with nutritional health awearness sessions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: nutritional health awareness sessions
Description: lifestyle changes and nutritional awareness sessions for 3 months twice a week for participants and their parents

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: nutritional health awareness sessions
Description: lifestyle changes and nutritional awareness sessions for 3 months twice a week for participants and their parents
Study: NCT06754007

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ROPES Training Programme
Description: ROPES is a training programme that involves resistance training, whole-body exercises and HIIT aerobic sessions with each session lasting no longer than 45 minutes.
Study: NCT06758297

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AI-Powered Motivational Speech
Description: It is known that patients with knee prosthesis have difficulty in the first standing process due to fears of falling, not being able to walk again, and recurrence of their disease. For this purpose, a speech text that will motivate patients was prepared with the support of ChatGPT. Expert opinions were obtained from 2 orthopedic specialists and 2 specialist psychiatric nurses for this speech text. Later, the speech text was converted into an audio video with the ElevenLabs application. Thus, it was planned to make it easier for patients to listen to it again. Patients will listen to this motivational speech in their own patient rooms and using their own headphones.
Study: NCT06756672

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HPI guidance
Description: patients with HPI guidance
Study: NCT05351346

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone PO will be administered as per the schedule specified in the respective arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone PO will be administered as per the schedule specified in the respective arm.
Study: NCT06186258

Intervention type: DEVICE
Intervention: percutaneous pulmonary valve implantation (PPVI)
Description: The only inclusion criterion is a successful PPVI to treat RVOT dysfunction. Procedural techniques were at each operator's discretion as well as post-procedure treatments and patient's follow-up. As we sought to assess IE incidence during follow-up, patients who underwent catheterization for intended PPVI but who did not had a successful valve implantation were not included. Successful PPVI was defined as patient discharged alive without valve surgery after successful valve implantation in the RVOT.
Study: NCT06756672

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: No HPI guidance
Description: patients without HPI guidance
Study: NCT06757231

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse Counseling Based on the Chronic Care Model (CCM)
Description: This intervention involves personalized nurse counseling for patients diagnosed with Inflammatory Bowel Disease (IBD) based on the Chronic Care Model. The intervention includes:~Biweekly phone consultations and weekly informational messages to provide education and support for symptom management, stress reduction, and quality-of-life improvement.~An educational booklet to aid self-management. Follow-ups to assess progress, address concerns, and provide guidance on IBD management strategies.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse Counseling Based on the Chronic Care Model (CCM)
Description: This intervention involves personalized nurse counseling for patients diagnosed with Inflammatory Bowel Disease (IBD) based on the Chronic Care Model. The intervention includes:~Biweekly phone consultations and weekly informational messages to provide education and support for symptom management, stress reduction, and quality-of-life improvement.~An educational booklet to aid self-management. Follow-ups to assess progress, address concerns, and provide guidance on IBD management strategies.
Study: NCT06758440

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chitosan
Description: Evaluate Effectiveness of hydroxyapatite reinforced chitosan hydrogel in modulation of osseintegration round immediate dental implant in a Randomized single blind control study
Study: NCT05351346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib
Description: Orelabrutinib PO will be administered as per the schedule specified in the respective arm.
Study: NCT05548582

Intervention type: DRUG
Group type: OTHER
Intervention: OxyCODONE 5 mg Oral Tablet
Description: No opioid prescription after laparoscopic hysterectomy
Study: NCT05351346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide PO will be administered as per the schedule specified in the respective arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine IV infusion will be administered as per the schedule specified in the respective arm.
Study: NCT06450548

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parametric acquisition
Description: Parametric acquisition for 18F-FDG PET/CT and 68GA-PSMA PET/CT with 24 h at 15 days of interval
Study: NCT05897879

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Nasopharyngeal swab
Description: For hospitalized patients :~Nasopharyngeal swab (1 aspiration or 2 swabs (1 in each nostril))~For ambulatory patients :~Deep nasal swab: 2 swabs (1 in each nostril), or 1 swab only for children for whom taking 2 swabs is complicated.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood samples
Description: For hospitalized patients : 3 to 7.5 ml For ambulatory patients: Fingertip blood sampling
Study: NCT04843709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRG004A
Description: Administrated intravenously
Study: NCT05548582

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen 500 mg Tab
Description: Standard prescription
Study: NCT05687279

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVt Vaccine
Description: Pharmaceutical Form: Suspension of virus in a nasal spray Route of Administration: Intranasal
Study: NCT05548582

Intervention type: DRUG
Group type: OTHER
Intervention: Acetaminophen 500 mg Tab
Description: Standard prescription

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 600 mg
Description: Standard prescription
Study: NCT05041270

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Surgery will be started under spinal anesthesia. When sensory block regress to T12 dermatome Epidural bolus dose will be given epidural bolus dose of 12ml (10ml 0.25% bupivacaine + 2ml normal saline) The onset of sensory blockade injected epiduraly with maximal cephalic spread will be assessed by bilateral pinprick method along the midclavicular line, every 5 min for 30 min and then every 30 min.~top up dose of 8ml will be given postoperative (6ml 0.25% bupivacaine + 2ml normal saline).
Study: NCT05548582

Intervention type: DRUG
Group type: OTHER
Intervention: Ibuprofen 600 mg
Description: Standard prescription
Study: NCT05041270

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Surgery will be started under spinal anesthesia. When sensory block regress to T12 dermatome Epidural bolus dose will be given epidural bolus dose of 12ml (10ml 0.25% bupivacaine + 100µg dexmedetomidine in 2ml volume) The onset of sensory blockade injected epiduraly with maximal cephalic spread will be assessed by bilateral pinprick method along the midclavicular line, every 5 min for 30 min and then every 30 min.~top up dose of 8ml will be given postoperative (6ml 0.25% bupivacaine + 20µg dexmedetomidine in 2ml volume).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nalbuphine
Description: Surgery will be started under spinal anesthesia. When sensory block regress to T12 dermatome Epidural bolus dose will be given epidural bolus dose of 12ml (10ml 0.25% bupivacaine + 10mg nalbuphine in 2ml volume) The onset of sensory blockade injected epiduraly with maximal cephalic spread will be assessed by bilateral pinprick method along the midclavicular line, every 5 min for 30 min and then every 30 min.~top up dose of 8ml will be given postoperative (6ml 0.25% bupivacaine + 2mg nalbuphine in 2ml volume).
Study: NCT06361017

Intervention type: PROCEDURE
Intervention: endovascular thrombectomy
Description: All individuals were anesthetized, with local or general anesthesia dependent on the cooperation level of the patient. During the procedure, it was mandatory to administer intravenous heparin to maintain the activated clotting time between 250 and 300 s, except for subjects who received intravenous alteplase. The procedures were performed through the femoral artery. The selection of stent retriever type and size, along with any required devices, such as guide wires and catheters, as well as the intervention strategy, was at the interventionists' discretion.
Study: NCT06182371

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Disengage the breathing circuit
Description: Disengage the breathing circuit when the position of the patient undergoing thoracic surgery changes
Study: NCT06361017

Intervention type: PROCEDURE
Intervention: endovascular thrombectomy
Description: All individuals were anesthetized, with local or general anesthesia dependent on the cooperation level of the patient. During the procedure, it was mandatory to administer intravenous heparin to maintain the activated clotting time between 250 and 300 s, except for subjects who received intravenous alteplase. The procedures were performed through the femoral artery. The selection of stent retriever type and size, along with any required devices, such as guide wires and catheters, as well as the intervention strategy, was at the interventionists' discretion.

Intervention type: PROCEDURE
Intervention: endovascular thrombectomy
Description: All individuals were anesthetized, with local or general anesthesia dependent on the cooperation level of the patient. During the procedure, it was mandatory to administer intravenous heparin to maintain the activated clotting time between 250 and 300 s, except for subjects who received intravenous alteplase. The procedures were performed through the femoral artery. The selection of stent retriever type and size, along with any required devices, such as guide wires and catheters, as well as the intervention strategy, was at the interventionists' discretion.

Intervention type: PROCEDURE
Intervention: endovascular thrombectomy
Description: All individuals were anesthetized, with local or general anesthesia dependent on the cooperation level of the patient. During the procedure, it was mandatory to administer intravenous heparin to maintain the activated clotting time between 250 and 300 s, except for subjects who received intravenous alteplase. The procedures were performed through the femoral artery. The selection of stent retriever type and size, along with any required devices, such as guide wires and catheters, as well as the intervention strategy, was at the interventionists' discretion.
Study: NCT04857580

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CTS Device
Description: Coronary cryotherapy is delivered locally on eligible lesions randomized to the treatment using the CTS System.
Study: NCT05587192

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-PSMA-1007 PET/CT based on diagnostic model
Description: All enrolled patients will receive 18F-PSMA-1007 PET/CT based USTC diagnostic model before gaining the final pathological diagnosis to be used as experimental arm.
Study: NCT04951505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cefepime-taniborbactam
Description: IV infusion
Study: NCT06069947

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sequential adult left lateral lobe liver transplantation (SALT)
Description: Hemihepatectomy combined with left lateral lobe liver transplantation was performed first, and residual liver resection was performed after the graft grew to a sufficient functional liver volume.
Study: NCT06579911

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-frequency micro-ultrasound target biopsy
Description: 1. High-frequency micro-ultrasound (transrectal ultrasound, 29 Hz, ExactVu) of the prostate. If suspicious lesions (PRIMUS \>= 3) other than those already detected in multiparametric MRI are found, target biopsy will be performed. Maximum of four cores per lesion.~2. Multiparametric MRI target biopsy (PI-RADS \>= 3) of the prostate (transrectal ultrasound, 29 Hz, ExactVu). Maximum of four cores per lesion.~3. Systematic biopsy (twelve cores) of the prostate

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional Multiparametric MRT target biopsy
Description: 1. Multiparametric MRT target biopsy (PI-RADS \>= 3) of the prostate (conventional transrectal ultrasound, 8-10 Hz). Maximum of four cores per lesion.~2. Systematic biopsy (twelve cores) of the prostate
Study: NCT06426706

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Serratus Posterior Superior Intercostal Plane Block
Description: Before the induction of general anesthesia, under aseptic conditions, serratus posterior superior intercostal plane block will be performed with a single dose of 30 ml of %0,25 bupivacaine with ultrasound guidance, by the senior anaesthesiologist.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Paravertebral Block
Description: Before the induction of general anesthesia, under aseptic conditions, paravertebral block will be performed with a single dose of 30 ml of %0,25 bupivacaine with ultrasound guidance, by the senior anaesthesiologist.
Study: NCT04592822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WD-1602
Description: dabigatran etexilate mesylate granules for oral suspension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pradaxa®
Description: dabigatran etexilate capsules